Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip Barter

Showing results (61-70 of 78) with videos related to

Pageof 8
Sort By:
International Journal of Cardiology|October 15, 2016
Consensus clinical recommendations for the management of plasma lipid disorders in the Middle EastNasreen Al Sayed, Khalid Al Waili, Fatheya Alawadi, et al.
Journal of Clinical Lipidology|November 7, 2017
Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular riskBenoit J Arsenault, Francine Petrides, Fatiha Tabet, et al.
American Heart Journal|September 29, 2009
Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapibChristopher P Cannon, Hayes M Dansky, Michael Davidson, et al.
The Lancet. Diabetes & Endocrinology|July 15, 2019
Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statementIan J Neeland, Robert Ross, Jean-Pierre Després, et al.
Clinica E Investigacion En Arteriosclerosis : Publicacion Oficial De La Sociedad Espanola De Arteriosclerosis|October 31, 2013
[Official document of the International Society of Atherosclerosis: general recommendations for treatment of dyslipidemia. Executive summary], Scott M Grundy, Hidenori Arai, et al.
Nature Reviews. Endocrinology|February 6, 2020
Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral ObesityRobert Ross, Ian J Neeland, Shizuya Yamashita, et al.
Circulation|June 4, 2008
Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatmentJohn J P Kastelein, Wim A van der Steeg, Ingar Holme, et al.
European Heart Journal|May 1, 2014
Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trialJean-Claude Tardif, Christie M Ballantyne, Philip Barter, et al.
JAMA|June 23, 2011
Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysisDavid Preiss, Sreenivasa Rao Kondapally Seshasai, Paul Welsh, et al.
Metabolism: Clinical and Experimental|May 14, 2016
Effects of the BET-inhibitor, RVX-208 on the HDL lipidome and glucose metabolism in individuals with prediabetes: A randomized controlled trialAndrew L Siebel, Si Khiang Trinh, Melissa F Formosa, et al.
Pageof 8

Showing results (61-70 of 78) with videos related to

Sort By:
Pageof 8
International Journal of Cardiology|October 15, 2016
Consensus clinical recommendations for the management of plasma lipid disorders in the Middle EastNasreen Al Sayed, Khalid Al Waili, Fatheya Alawadi, et al.
Journal of Clinical Lipidology|November 7, 2017
Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular riskBenoit J Arsenault, Francine Petrides, Fatiha Tabet, et al.
American Heart Journal|September 29, 2009
Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapibChristopher P Cannon, Hayes M Dansky, Michael Davidson, et al.
The Lancet. Diabetes & Endocrinology|July 15, 2019
Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statementIan J Neeland, Robert Ross, Jean-Pierre Després, et al.
Clinica E Investigacion En Arteriosclerosis : Publicacion Oficial De La Sociedad Espanola De Arteriosclerosis|October 31, 2013
[Official document of the International Society of Atherosclerosis: general recommendations for treatment of dyslipidemia. Executive summary], Scott M Grundy, Hidenori Arai, et al.
Nature Reviews. Endocrinology|February 6, 2020
Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral ObesityRobert Ross, Ian J Neeland, Shizuya Yamashita, et al.
Circulation|June 4, 2008
Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatmentJohn J P Kastelein, Wim A van der Steeg, Ingar Holme, et al.
European Heart Journal|May 1, 2014
Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trialJean-Claude Tardif, Christie M Ballantyne, Philip Barter, et al.
JAMA|June 23, 2011
Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysisDavid Preiss, Sreenivasa Rao Kondapally Seshasai, Paul Welsh, et al.
Metabolism: Clinical and Experimental|May 14, 2016
Effects of the BET-inhibitor, RVX-208 on the HDL lipidome and glucose metabolism in individuals with prediabetes: A randomized controlled trialAndrew L Siebel, Si Khiang Trinh, Melissa F Formosa, et al.
Pageof 8